APOE and in situ carcinoma: People carrying the ApoE4 allele are at high risk of AD and have alterations in BBB function (201), and it was recently shown that ApoE4 may predict cognitive decline in CIS and early RRMS patients (237), however not directly linked to vascular dysfunction.